More than 200,000 prescriptions for copies of Novo Nordisk’s (NYSE: NVO) weight-loss drug Wegovy are getting filled by U.S. patients
1 year ago
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk’s (NYSE: NVO) highly in-demand drugs for diabetes
LONDON – Novo Nordisk’s (NYSE: NVO) sales growth next year could be in the high teens in percentage terms, Chief
COPENHAGEN – Novo Nordisk (NYSE: NVO) is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States
COPENHAGEN – On Wednesday, Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug, reassuring investors worried that
LONDON – On Wednesday, Novo Nordisk (NYSE: NVO) chief financial officer Karsten Munk Knudsen said the company was aware of
Americans are still eagerly seeking prescriptions for Eli Lilly’s (NYSE: LLY) and Novo Nordisk’s (NYSE: NVO) weight-loss and diabetes drugs
BRUSSELS/LONDON – EU antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer
NEW YORK – Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk (NYSE: NVO) and
On Monday, Novo Nordisk (NYSE: NVO) said an oral version of its drug semaglutide, helped significantly reduce the risk of
NEW YORK – On Thursday, U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission to
BENGALURU – Novo Nordisk (NYSE: NVO), whose global profile has risen along with demand for its Wegovy weight-loss drug, is
